Skip to content

Desbuquois Dysplasia 2 C4014294

Published: July 22, 2026Updated: August 27, 2026

A rare genetic skeletal disorder causing short stature, joint laxity, and distinctive facial features due to abnormal bone development.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Joint pain or stiffness

(musculoskeletal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Severe short stature

(musculoskeletal)

Joint hypermobility

(musculoskeletal)

Vertebral abnormalities

(musculoskeletal)

Delayed motor milestones

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Corrective orthopedic procedures

Surgical intervention for severe skeletal manifestations including spine and extremity deformities using age-appropriate techniques and careful perioperative planning.

surgical
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Functional rehabilitation program

Comprehensive therapy program addressing joint hypermobility, muscle strengthening, and functional skills to maintain independence and prevent deterioration.

physical_therapy

Additional treatment options

Comprehensive multidisciplinary follow-up

Regular coordinated assessments by orthopedic, rehabilitation, and developmental specialists to monitor disease course and treatment response.

monitoring

Activity modification and joint protection

Education on appropriate activity levels, joint protection techniques, and avoidance of high-impact activities to minimize skeletal stress and prevent injury.

lifestyle

Pain management and inflammatory control

Pharmacological approaches to address chronic pain and inflammatory flares associated with skeletal abnormalities using appropriate therapeutic agents.

medication

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Desbuquois Dysplasia 2 C4014294?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Desbuquois Dysplasia 2 C4014294. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy